logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Insulin Analog class drugs

    FiltersReset Filters
    10 results

    • admelog

      (insulin lispro)
      Sanofi-Aventis U.S. LLC
      Usage: ADMELOG is indicated for improving glycemic control in both adult and pediatric patients with diabetes mellitus.

    • apidra

      (insulin glulisine)
      sanofi-aventis U.S. LLC
      Usage: APIDRA is indicated for improving glycemic control in both adult and pediatric patients with diabetes mellitus.

    • basaglar

      (Insulin glargine)
      Eli Lilly and Company
      Usage: BASAGLAR® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus. It is not recommended for treating diabetic ketoacidosis.

    • fiasp

      (insulin aspart injection)
      Novo Nordisk
      Usage: FIASP is indicated for improving glycemic control in both adult and pediatric patients with diabetes mellitus.

    • humalog

      (Insulin lispro)
      Eli Lilly and Company
      Usage: HUMALOG Mix75/25 is indicated for improving glycemic control in adults with diabetes mellitus. It has fixed proportions of rapid-acting and intermediate-acting insulins, limiting adjustments for basal and prandial doses.

    • humalog

      (Insulin lispro)
      Eli Lilly and Company
      Usage: HUMALOG Mix50/50 is indicated for improving glycemic control in adults with diabetes mellitus. However, it has limitations as the fixed proportions of rapid-acting and intermediate-acting insulins prevent adjustments for basal and prandial dosing.

    • levemir

      (insulin detemir)
      Novo Nordisk
      Usage: LEVEMIR is indicated for improving glycemic control in adults and pediatric patients with diabetes mellitus. It is not recommended for treating diabetic ketoacidosis.

    • lyumjev

      (Insulin lispro-aabc)
      Eli Lilly and Company
      Usage: LYUMJEV® is indicated for improving glycemic control in both adult and pediatric patients with diabetes mellitus.

    • toujeo

      (insulin glargine)
      Sanofi-Aventis U.S. LLC
      Usage: TOUJEO is indicated for improving glycemic control in adults and pediatric patients aged 6 years and older with diabetes mellitus. It is not recommended for treating diabetic ketoacidosis.

    • tresiba

      (insulin degludec)
      Novo Nordisk
      Usage: TRESIBA is indicated for improving glycemic control in patients aged 1 year and older with diabetes mellitus. It is not recommended for treating diabetic ketoacidosis.